

Peter Sandner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9642142/publications.pdf>

Version: 2024-02-01

52
papers

1,671
citations

279798

23
h-index

302126

39
g-index

57
all docs

57
docs citations

57
times ranked

1660
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5146-5161.	6.4	133
2	Soluble Guanylate Cyclase Stimulators and Activators. <i>Handbook of Experimental Pharmacology</i> , 2018, 264, 355-394.	1.8	104
3	Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGF β 2 signalling. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1408-1416.	0.9	92
4	cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function. <i>Nature Medicine</i> , 2012, 18, 252-259.	30.7	82
5	cGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2020, 393, 287-302.	3.0	82
6	Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence. <i>Respiratory Medicine</i> , 2017, 122, S1-S9.	2.9	79
7	Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 225-247.	1.8	77
8	Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1019-1026.	0.9	74
9	From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators. <i>Biological Chemistry</i> , 2018, 399, 679-690.	2.5	62
10	Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1621-1625.	0.9	60
11	The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1712.	4.1	60
12	Vardenafil Decreases Bladder Afferent Nerve Activity in Unanesthetized, Decerebrate, Spinal Cord – Injured Rats. <i>European Urology</i> , 2011, 59, 272-279.	1.9	57
13	Nitric Oxide/cAMP Interactions in the Control of Rat Renal Vascular Resistance. <i>Circulation Research</i> , 1999, 84, 186-192.	4.5	55
14	Soluble GC stimulators and activators: Past, present and future. <i>British Journal of Pharmacology</i> , 2021, , .	5.4	45
15	Emerging strategies for treatment of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 186-193.	1.7	41
16	Loss of smooth muscle CYB5R3 amplifies angiotensin II – induced hypertension by increasing sGC heme oxidation. <i>JCI Insight</i> , 2019, 4, .	5.0	39
17	Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042). <i>Journal of Medicinal Chemistry</i> , 2021, 64, 5323-5344.	6.4	38
18	Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases. <i>Nitric Oxide - Biology and Chemistry</i> , 2018, 77, 88-95.	2.7	30

#	ARTICLE	IF	CITATIONS
19	Enhanced Cardiomyocyte Function in Hypertensive Rats With Diastolic Dysfunction and Human Heart Failure Patients After Acute Treatment With Soluble Guanylyl Cyclase (sGC) Activator. <i>Frontiers in Physiology</i> , 2020, 11, 345.	2.8	29
20	The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review. <i>Gerontology</i> , 2017, 63, 216-227.	2.8	29
21	Inhibition of the $\text{TGF}\beta^2$ signalling pathway by cGMP and cGMP-dependent kinase I in renal fibrosis. <i>FEBS Open Bio</i> , 2017, 7, 550-561.	2.3	27
22	Nitric oxide-sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction. <i>JCI Insight</i> , 2018, 3, .	5.0	27
23	Nitric Oxide-independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 58, 636-647.	2.9	25
24	Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells. <i>Experimental Cell Research</i> , 2015, 338, 162-169.	2.6	24
25	NO-Sensitive Guanylate Cyclase Isoforms NO-GC1 and NO-GC2 Contribute to Noise-Induced Inner Hair Cell Synaptopathy. <i>Molecular Pharmacology</i> , 2017, 92, 375-388.	2.3	24
26	Mind the gap (junction): cGMP induced by nitric oxide in cardiac myocytes originates from cardiac fibroblasts. <i>British Journal of Pharmacology</i> , 2019, 176, 4696-4707.	5.4	23
27	Soluble guanylate cyclase stimulators and their potential use: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 203-222.	5.0	22
28	Soluble Guanylate Cyclase Agonists Induce Bronchodilation in Human Small Airways. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2020, 62, 43-48.	2.9	16
29	Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney. <i>British Journal of Pharmacology</i> , 2021, , .	5.4	14
30	Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator. <i>Journal of Pathology</i> , 2022, 256, 442-454.	4.5	14
31	From bedside to bench meeting report of the 7th International Conference on cGMP & sGC: generators, effectors and therapeutic implications in Trier, Germany, from June 19th to 21st 2015. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 1237-1246.	3.0	13
32	Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 2363-2379.	3.0	13
33	Phosphodiesterase 5 inhibitors and erectile dysfunction. <i>Expert Opinion on Therapeutic Patents</i> , 2008, 18, 21-33.	5.0	12
34	The Three-Decade Long Journey in Heart Failure Drug Development. <i>Handbook of Experimental Pharmacology</i> , 2016, 243, 1-14.	1.8	12
35	Erectile Dysfunction and Lower Urinary Tract. <i>Handbook of Experimental Pharmacology</i> , 2009, , 507-531.	1.8	12
36	Protein Kinase G Is Involved in Acute but Not in Long-Term Regulation of Renin Secretion. <i>Frontiers in Pharmacology</i> , 2019, 10, 800.	3.5	11

#	ARTICLE	IF	CITATIONS
37	A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGC. <i>Biochemical Pharmacology</i> , 2019, 163, 142-153.	4.4	11
38	BAY 602770 activates two isoforms of nitric oxide sensitive guanylyl cyclase: Evidence for stable insertion of activator drugs. <i>Biochemical Pharmacology</i> , 2018, 147, 10-20.	4.4	10
39	Soluble Guanylate Cyclase Stimulator Vericiguat Enhances Long-Term Memory in Rats without Altering Cerebral Blood Volume. <i>Biomedicines</i> , 2021, 9, 1047.	3.2	10
40	Thermal shift assay: Strengths and weaknesses of the method to investigate the ligand-induced thermostabilization of soluble guanylyl cyclase. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 181, 113065.	2.8	8
41	Effects of PDE5 Inhibitors and sGC Stimulators in a Rat Model of Artificial Ureteral Calculosis. <i>PLoS ONE</i> , 2015, 10, e0141477.	2.5	7
42	Transcutaneous glomerular filtration rate measurement in a canine animal model of chronic kidney disease. <i>Journal of Pharmacological and Toxicological Methods</i> , 2018, 90, 7-12.	0.7	7
43	Riociguat for the treatment of Phe508del homozygous adults with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 1018-1025.	0.7	5
44	Tyrosine 135 of the β 1 subunit as binding site of BAY-543: Importance of the Y-x-S-x-R motif for binding and activation by sGC activator drugs. <i>European Journal of Pharmacology</i> , 2020, 881, 173203.	3.5	5
45	The sGC stimulator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanisms. <i>Scientific Reports</i> , 2022, 12, 3589.	3.3	5
46	Testosterone Induces Relaxation of Human Corpus Cavernosum Tissue of Patients With Erectile Dysfunction. <i>Sexual Medicine</i> , 2020, 8, 114-119.	1.6	3
47	Assessing the Use of the sGC Stimulator BAY-747, as a Potential Treatment for Duchenne Muscular Dystrophy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8016.	4.1	3
48	sGC stimulation lowers elevated blood pressure in a new canine model of resistant hypertension. <i>Hypertension Research</i> , 2021, 44, 1568-1577.	2.7	2
49	Vericiguat Improves Aortic Wave Reflection Parameters in a New Preclinical Model of Hypertension. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008735.	3.9	2
50	Urinary miRNA Profiles in Chronic Kidney Injury—Benefits of Extracellular Vesicle Enrichment and miRNAs as Potential Biomarkers for Renal Fibrosis, Glomerular Injury, and Endothelial Dysfunction. <i>Toxicological Sciences</i> , 2022, , .	3.1	2
51	Capillary hemodynamics and contracting skeletal muscle oxygen pressures in male rats with heart failure: Impact of soluble guanylyl cyclase activator. <i>Nitric Oxide - Biology and Chemistry</i> , 2021, 119, 1-1.	2.7	1
52	In Vivo Screening for Cystic Fibrosis Drugs: Transfer of Clinical Readout Parameters in CF Patients to the delF508 CFTR CF Mice. <i>FASEB Journal</i> , 2015, 29, 775.9.	0.5	0